Novartis has lost its bid to have Pharmacor’s claim that its patent for a blood pressure drug is invalid decided ahead of a main trial where the Swiss pharmaceutical giant will allege the generic drug maker is threatening to infringe its patent.
Ferroglobe has claimed a Queensland technology company used its confidential information in new patent applications, as the global specialty metals producer races to protect its IP before the applications are published.
A judge has found Shenzhen-based based radio manufacturer Hytera engaged in “substantial industrial theft” by appropriating Motorola’s source code for its digital mobile radios and should be on the hook for additional damages for “flagrantly” infringing Motorola’s copyright.
Novartis and and generic drug maker Pharmacor have resolved litigation over the Swiss pharmaceutical giant’s patents for blockbuster MS drug Gilenya.
Swiss pharmaceutical company Biogen and Australian generic drug maker Pharmacor have dropped their claims against one another in a lawsuit over the patent for MS drug Tecfidera. In an October 14 order by Federal Court Justice Helen Rofe, Biogen’s infringement claims and Pharmacor’s cross-claims seeking to invalidate the lucrative patent were discontinued by consent without…
Twenty barristers have risen to the ranks of senior counsel in New South Wales, including a veteran defamation barrister, two counsel with class action expertise and part of the team that saw ASIC’s claims against two Rio Tinto executives dropped.
A judge has thrown out competing appeals of a decision finding Pfizer’s patent for its post-operative injectable painkiller Dynastat is valid and that Australian drug maker Juno Pharmaceuticals infringed the patent by selling generic versions of the drug in Australia.
Bangkok Broadcasting and Seven Networks have settled two lawsuits over the Thai broadcaster’s registration of ‘7’ marks in Australia.
Pharmaceutical giant Pfizer has fired off a lawsuit against four drug companies for allegedly infringing one of its patents for biologic Enbrel by selling a biosimilar of the blockbuster arthritis drug in Australia.
The Full Federal Court won’t give Swiss pharmaceuticals giant Novartis the chance to appeal a ruling that threw out three of its four experts in a patent case against generic drug maker Pharmacor.